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Intrinsic Akt1 activation through SOX9-mediated mTOR regulation is obligatory for BCC
pathogenesis in a murine model of nevoid basal cell carcinoma syndrome (NBCCS)
AL Kim,1 J Back,1 Y Zhu,1 X Tang,1 M Athar2 and DR Bickers1 1 Dermatology, Columbia
University, New York, NY and 2 University of Alabama at Birmingham, Birmingham, AL
Germline Ptch 1 mutations activate sonic hedgehog (Shh) signaling that drives the growth of basal
cell carcinomas (BCC) in NBCCS but recent studies suggest involvement of additional pathways.
Akt1/PKB is a serine/threonine protein kinase that controls cell proliferation and survival. Ker-
atinocytes constitutively overexpressing myristoylated Akt1 undergo colony formation while resist-
ing UV-induced apoptosis. Akt1 phosphorylates mTOR, which in turn phosphorylates Akt1 S473,
facilitating its full activation. S473 Akt1 phosphorylation occurs in human BCCs and in spontaneous
and UVB-induced BCCs in Ptch1+/-/SKH-1 mice, our murine model of NBCCS. Here we assessed
the possible role of Akt1 in spontaneous BCC pathogenesis. We show increased mTOR mRNA and
Akt1 S473 phosphorylation in keratinocytes isolated from newborn Ptch1+/–/SKH-1 mice. Next,
using murine ASZ001 BCC cells, we show that cyclopamine, a Smoothened inhibitor, suppresses
S473 phosphorylation whereas LY294002, a PI3K inhibitor, selectively suppresses T308 phospho-
rylation showing that Akt1 S473 phosphorylation is downstream of Shh in BCC cells. We also
found that the promoter region of mTOR possesses binding motifs for Sry-related HMG box 9 (SOX9),
a Gli-regulated transcription factor in the Shh pathway. Both endogenous and recombinant SOX9
proteins directly bind to the mTOR promoter in Ptch1+/–/SKH-1 mice in vivo, as assessed by chro-
matin immunoprecipitation. Genetic ablation of SOX9 in BCC cells diminished both this binding
and the expression of mTOR, thereby blocking phosphorylation of well-characterized mTOR sub-
strates including p7056K and 4E-BP1. Finally we generated Akt1+/-/Ptch1+/-/SKH-1 mice and
abolished spontaneous and UVB-induced BCCs in these animals. Our data show that Shh signal-
ing intrinsically activates Akt1 via the SOX9-mTOR regulatory axis suggesting that Akt1 is a poten-
tial target for pharmacological inhibition of BCC pathogenesis in patients with NBCCS.
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Histone deacetylase inhibitor MS-275 restored retinoid sensitivity and had an antitumor effect
in combination with retinoic acid Am80 in human cutaneous T cell lymphoma
Y Kato, C Egusa, T Maeda and R Tsuboi Dermatology, Tokyo Medical University, Shinjuku,
Japan
Resistance to chemotherapy is a major hurdle in the treatment of cutaneous T cell lymphoma. His-
tone deacetylase (HDAC) inhibitors are known to display antitumor activity in different tumor
types, including melanoma, and to reverse epigenetic repression of tumor suppressor genes. Some
HDAC inhibitor has begun to be used for cutaneous T cell lymphoma patients in Japan. In this
study, we tested the antitumor effect of the HDAC inhibitor MS-275 in combination with retinoic
acid Am80 on two human cutaneous T cell lymphoma cell lines in vitro and in vivo. Treatment of
MS-275 showed a dose-dependent inhibitory effect on SeAx and MJ cell lines in a XTT assay. These
cell lines were relatively resistant to Am80. A greater inhibitory effect (up to 80%) was achieved
with a combination of MS-275 and Am80 compared with each agent alone. The lack of RARβ2 gene
expression was associated with histone deacetylation and gene methylation at the promoter level.
Treatment with the combination of MS-275 and Am80 restored retinoid sensitivity by reversing
RARβ2 epigenetic silencing, which was verified by ChIP assay using histone H4. P21 was induced
in both cell lines but the biological effect of MS-275 was G1cell cycle arrest in MJ and apoptosis
in the SeAx cell line. Tumor volume analysis in NOD scid mice showed that the treatment of the
combination of MS-275 and Am80 had a significant inhibitory effect on tumor growth in vivo. These
results suggest that the HDAC inhibitor MS-275 restores the sensitivity of retinoic acid and has a
greater antitumor activity in combination with Am80 in cutaneous T cell lymphomas by reverting
epigenetic silencing of RARβ2. The combination of HDAC inhibitors and retinoids represents a novel
therapeutic approach for cutaneous T cell lymphoma that warrants clinical testing.
202 
Tumor Cell Associated Receptor Tyrosine Kinase, EphB2 regulates proliferation, migration and
invasion of cutaneous SCC
M Farshchian,1 L Nissinen,1 E Siljamäki,1 R Ala-aho,1 R Grénman,2 J Peltonen3 and V Kähäri1 1
Department of Dermatology, and MediCity Research Laboratory, University of Turku, Turku,
Finland, 2 Department of Otorhinolaryngology, Head and Neck Surgery, University of Turku,
Turku, Finland and 3 Department of Anatomy and Cell Biology, University of Turku, Turku,
Finland
Non-melanoma skin cancer, including BCC and SCC are the most common types of human can-
cers in the white populations. Erythropoietin-producing hepatocellular (Eph) receptors represent the
largest family of receptor tyrosine kinases. Affymetrix-based expression profiling and SOLiD™ whole
transcriptome analysis of the expression of Eph receptors and their ligands in cutaneous SCC cell
lines (n=8) and normal human epidermal keratinocytes (NHEK) (n=5) revealed specific up-regula-
tion of EphB2 mRNA in SCC cells. Up-regulation of EphB2 mRNA was also noted by quantitative
RT-PCR in SCC tumors compared with normal skin. Western blot analysis and indirect immunoflu-
orescence showed presence of EphB2 on surfarce of all SCC cell lines, but not on NHEK. High
EphB2 expression level was also noted in invasive tumorigenic Ha-ras-transformed HaCaT cell
line. Tumor cell-specific expression of EphB2 was also noted in cutaneous SCC tissue sections by
immunohistochemistry. Knock-down of EphB2 expression with specific siRNA significantly decreased
proliferation, migration and invasion of skin SCC cells. Affymetrix-based gene expression profiling
identified 2460 differentially regulated genes (P<0.05) after EphB2 receptor knock-down in SCC
cells, vimentin as the most up regulated gene and SerpinB3, MMP-1 and MMP-13 among the most
down-regulated genes. Ingenuity Pathway Analysis revealed association of the EphB2 receptor with
cancer as the top biofuntion of the diseases and disorders. Activation of EphB2 by specific ligand
induced activation of ERK1/2 and p38 MAPK signaling, expression of MMP-13, and cell adhesion
to collagen in SCC cells. Taken together these data provide evidence for the role of EphB2 signal-
ing in progression of cutaneous SCC, suggesting it as a potential therapeutic target in these invasive
and metastatic tumors.
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Stat1-signaling protects from metastases in endogenous cancers
E Brenner, H Braumüller, T Wieder and M Röcken Eberhard-Karl University, Tübingen, Germany
Immunotherapy with tumor-specific Th1 cells doubles life span in mice with neuroendocrine can-
cers. Previous studies indicated that the therapeutic effect of CD4+ T cells depends on interferon-γ
(IFN-γ) and tumor necrosis factor (TNF). To elaborate the underlying mechanisms and the immune
cells involved in vivo, we generated tumor bearing mice lacking the signal transducer and activa-
tor of transcription 1 (Stat1), a critical component of the IFN-signaling cascade. Neuroendocrine
cancers develop because of expression of large T antigen 2 (Tag) of the SV40 under the control of
the rat insulin promoter 1 (RIP1-Tag mice). RIP1-Tag2xStat1.ko mice developed the same number
of islet carcinomas, blood glucose decreased at the same time and the survival was identical to that
of RIP1-Tag2 controls. In sharp contrast to RIP1-Tag2 mice that never develop metastases, about
50% of RIP1-Tag2xStat1.ko mice developed metastasis in mesenteric lymph nodes. To address the
underlying mechanism we compared gene expression pattern of tumors ex vivo. The expression
data suggest that Stat1 critically controls cell motility and invasiveness via induction of epithelial
differentiation markers E-cadherin, Keratin-7 and Desmoplakin, and suppression of the mesenchy-
mal marker Foxc2. Moreover, Th1 cells failed to prolong the survival of RIP1-Tag2xStat1.ko mice,
highlighting the importance of the IFN-γ-signaling for Th1 cell based immunotherapy. To investigate
the immune cell involvement during therapy, we analyzed immune cell infiltration via flow cytom-
etry of Th1-treated and sham-treated RIP1-Tag2xStat1.ko mice. First expression analyses suggest that
Th1 cells protect from cancer progression and metastases through the induction of the chemokine
CXCL9 and the inducible nitric oxide synthase (iNOS), mediators known to be involved in the IFN-
γ-mediated control of viral and parasitic infections. Thus, Stat1-signaling is crucial to protect from
endogenously developing metastases by adaptive immunity in a model of multistage carcinogene-
sis.
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Analysis of the role of Gasc1 in skin carcinogenesis
H Yumi,1 F Kyoko,2 I Maki,3 K Motoaki,2 O Asako,2 I Jun,2 T Tadashi,1 I Johji,4 N Hiroki5 and
S Masayoshi2 1 dermatology, Nihon university school of medicine, Itabashi-ku, Japan, 2 inter-
nal medicine, Nihon university graduate school of medicine, Itabashi-ku, Japan, 3 social med-
icine, Nihon university graduate school of medicine, Itabashi-ku, Japan, 4 Molecular
Cytogenetics, Tokyo Medical and Dental University, Shinjuku-ku, Japan and 5 Cancer
Genetics, Chiba Cancer Center Research Institute, Chiba-shi, Japan
GASC1 encodes a histone demethylase catalyzing lysine (K) of histone, specifically K9 and K36 of
histone H3. It has been reported that GASC1 is located within an amplicon at 9p23-24 frequently
in esophageal cancer and overexpressed in undifferentiated ES cells and breast cancer. Since these
reports suggest the involvement of GASC1 in carcinogenesis, we generated Gasc1 knockout mice
to analyze the role of GASC1. It was shown that Het mice developed without any remarkable phe-
notype, while homozygous mice are embryonic lethal. The progenies, including 28 Het and 24
wild-type mice, were treated with the two-stage chemical carcinogenesis protocol on their back
skin. Het mice showed significantly lower incidence and multiplicity of both benign and malignant
skin tumors than those in wild-type. To identify genes involved in skin tumor resistance in the Het,
expression profiling of the skin samples obtained from Het and wild-type mice were analyzed
using Agilent whole genome microarrays. We found that in general cell adhesion related genes were
up-regulated and hormonal and immune system related genes were down-regulated in Het mice
compared to those in wild-type. Those may be candidates for the genes mediating the function of
GASC1 and we analyzed methylation status of histone H3K9 and GASC1 binding at the promoter
region of those candidate genes to prove direct involvement of Gasc1 during skin tumor carcino-
genesis. By ChIP assay, we found that H3K9 at the promoter region of one candidate gene is more
highly methylated in Het than in wild type. This result indicates that the candidate could be a direct
target of Gasc1 and mediating tumor promoting effect of Gasc1.
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Suppression of effector T cell responses by regulatory T cells in human skin squamous cell
carcinomas
C Lai,1 S August,1 C McGuire,1 M Polak,1 J Theaker,2 M Ardern-Jones,1 C Pickard,1 A Al-
Shamkhani3 and E Healy1 1 Dermatopharmacology, University of Southampton, Southampton,
United Kingdom, 2 Histopathology, University Hospital Southampton NHS Foundation Trust,
Southampton, United Kingdom and 3 Cancer Sciences, University of Southampton,
Southampton, United Kingdom
The evasion of anti-tumour immune responses plays a significant role in skin cancer pathogenesis.
This is particularly evident in immunosuppressed organ transplant recipients, in whom the inci-
dence of cutaneous squamous cell carcinoma (SCC) is dramatically increased. Peritumoral immune
cell infiltrates are frequently observed in SCCs in immunocompetent subjects, but these immune
cells fail to prevent cancer development and progression. FOXP3+ regulatory T cells (Tregs) are con-
sidered important in limiting anti-tumour immunity, and our previous work has identified that FOXP3+
Tregs are present in SCCs and precancerous skin lesions. Flow cytometric analysis of the peritu-
moral infiltrate in cutaneous SCCs showed that CD3+CD4+ cells comprised a lower proportion of
the CD3+ population in the SCC infiltrate compared with in peripheral blood (49.7% versus 68.8%,
n=15, p=0.027), but there were significantly more CD3+CD8+ cells in the tumour than in the blood
(40.0% versus 18.3% of CD3+ cell population, n=15, p<0.001). In addition,
CD3+CD4+CD25hiCD127loFOXP3+ Tregs were more abundant surrounding the tumour compared
with peripheral blood (21.8% versus 6.8% of CD3+CD4+ population, n=28, p<0.001). Confocal
microscopy of SCCs confirmed that CD4+FOXP3+ Tregs were frequently in direct contact with CD4+
or CD8+ effector cells. In vitro add-back assays demonstrated that flow cytometry-sorted peritu-
moral CD3+CD4+CD25hi Tregs suppressed proliferation of phytohaemagglutinin-stimulated peri-
tumoral CD3+CD4+CD25lo effector cells (mean suppression = 42.6%, n=10, p=0.005) and peri-
tumoral CD3+CD8+ effector cells (mean suppression = 15.8%, n=9, p=0.015). These results indicate
that Tregs accumulate in SCCs and suppress peritumoral effector T cell responses, suggesting Tregs
allow these tumours to avoid immune-mediated clearance.
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Desmoglein 3 regulates cancer cell migration through Protein Kinase C dependent-ezrin acti-
vation
LE Brown,1 E Gunic,1 M Unadkat,1 T Mannan,1 S Tsang,1 W Ahmed,1 F Valderrama,2 EA O’Toole3
and H Wan1 1 Clinical and Diagnostic Oral Science, Queen Mary University of London,
Institute of Dentistry, London, United Kingdom, 2 Biomedical Sciences, St George’s, University
of London, London, United Kingdom and 3 Centre for Cutaneous Research, Queen Mary
University of London, Blizard Institute, London, United Kingdom
This study aims to investigate the extra-junctional functions of desmosomal cadherin Desmoglein
3 (Dsg3), in the regulation of actin based cellular processes such as cell morphology, motility and
migration through the activation of Ezrin/Radixin/Moesin (ERM) family proteins. We have gener-
ated stable cell lines, A431 and SqCC/Y1, over expressing full length Dsg3. RNAi-mediated knock-
down was used to ascertain the specificity of our observations. Cell migration and invasion were
assessed by transwell and organotypic invasion assays. Dsg3 and Ezrin colocalisation were exam-
ined using the Proximity ligation Assay, confocal microscopy and FRET analysis. Complex forma-
tion was determined by co-Immunoprecipitation and finally, pharmacological inhibitors were used
to elucidate possible signalling mechanisms involved. Increased expression of Dsg3 amplified phos-
phorylation of ERM proteins, most significantly Ezrin-Thr567, that coincides with augmented mem-
brane protrusions, cell spreading, migration and invasion. We demonstrate that Dsg3 colocalises
and forms complex with ezrin at the plasma membrane, in a dose dependent manner, that appears
essential to interactions between Ezrin and F-actin or CD44 since Dsg3 depletion caused signifi-
cant reduction of their colocalisation and collapse of membrane protrusions. Furthermore, enhanced
ERM phosphorylation could be abrogated by the pharmacological inhibitors for Ser/Thr kinases
including PKC and ROCK known to activate Ezrin. Our data suggests a novel signaling role of Dsg3
in regulating ERM phosphorylation and subsequent actin based cell migration, invasion and metas-
tasis. These finding will not only further our understanding of Dsg3’s role in tumor cell biology but
also has implications in pemphigus pathogenesis and other cell adhesion diseases.
208
Functional inactivation of CYLD increases the malignancy of tumor epidermal cells and
enhances their metastatic potential
L Casanova,1 JP Alameda,1 MJ Fernandez-Aceñero,2 R Quintana,1 A Page,1 A Ramirez,1 A Bravo3
and M Navarro1 1 Molecular Oncology, CIEMAT, Madrid, Spain, 2 Department of Pathology,
Fundacion Jimenez Diaz, Madrid, Spain and 3 Department of Veterinary Clinical Sciences,
University of Santiago de Compostela, Lugo, Spain
We have studied the role that CYLD plays in the progression and metastasis of squamous cell car-
cinomas of the skin. For this purpose we have performed in vitro studies in tumorigenic epidermal
cells as well as in vivo xenograft carcinogenesis assays and metastasis experiments in nude mice.
CYLD is a tumor suppressor gene mutated in familial cylindromatosis, a disease that predisposes to
the development of skin appendages tumors (cylindromas, trichoepitheliomas and spiradenomas).
Recent studies have associated CYLD down-regulation with the development of other types of human
cancer including tumors of colon, lung and kidney, as well as melanomas and cervical and hepa-
tocellular carcinomas. We demonstrate that the expression in tumorigenic epidermal cells of a cat-
alytically inactive form of CYLD (CYLDC/S) that mimics the mutations of cyld identified in human
tumors and competes with the endogenous CYLD results in enhanced cell proliferation and inhi-
bition of apoptosis; it also stimulates cell migration and induces the expression of angiogenic fac-
tors, including vascular endothelial growth factor-A. Altogether, these characteristics indicate an
increased oncogenicity of the tumorigenic epidermal CYLDC/S mutant cells in vitro. Moreover, we
show an increase in the malignancy of epidermal squamous cell carcinomas that express the CYLDC/S
transgene in an in vivo xenograft model. We have also performed in vivo metastasis assays in nude
mice and found that the loss of function of CYLD in tumor epidermal cells greatly enhances the
capability of these cells to metastasize in lungs. Therefore, our results assign a role for CYLD as epi-
dermal tumor repressor and suppressor of skin cancer metastasis.
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Exome level sequencing identifies candidate genes mutated in cutaneous squamous cell car-
cinoma progression
AP South,1 KJ Purdie,2 SA Watt,1 CA Harwood,2 C Proby1 and IM Leigh1 1 Dermatology and
Genetic Medicine, University of Dundee, Dundee, United Kingdom and 2 Cutaneous
Research, Barts and The London, London, United Kingdom
Cutaneous Squamous Cell Carcinoma (cSCC) is the most frequent epithelial skin cancer with malig-
nant potential contributing to over 1 in 4 skin cancer deaths in the UK. Patients presenting with
lymph node metastasis have a poor 5 year survival, reported to be as low as 25%. Tumour differ-
entiation, determined by the degree of keratinization and cellular atypia, predicts progression: a
greater percentage of poorly differentiated (PD) SCCs metastasise compared with well-differentiated
(WD) counterparts. In order to identify genetic mutation associated with cSCC progression we have
sequenced 40 exomes from 20 patients comprising 10 PD cSCC, 10 WD cSCC and matched leuko-
cyte or normal skin DNA. All tumour samples were microdissected from fresh frozen tissue. Agi-
lent SureSelect enriched exome DNA was sequenced using Illumina technology. Specialist Sequenc-
ing (and Bioinformatics) were provided by the EASIH - University of Cambridge supported by NIHR
- Cambridge BRC. Mutations were scored as present in tumour DNA and absent in germline (blood
or skin) DNA. Our data show that mutation rates (determined by those SNPs present in tumour and
absent in germ line DNA) across all cSCC ranged from 0.8 to 3.9 mutations per 30,000 base pairs
of sequence with an overall average of 2.2. Poorly differentiated tumours averaged 2.6 mutations/
30Kb while WD tumours averaged 1.8 mutations/ 30kb. Deleterious mutation rates (determined by
tumour specific SNPs not present in reference databases) were significantly higher in PD tumours
(average 1227.2) than WD tumours (average 652.2). 10 genes were identified as being mutated in
50% or more PD tumours only: no mutations were identified for these genes in any of the WD
tumours. Two of these PD specific genes were mutated in 70% and 80% of PD tumours. Validation
in a larger sample set and functional analysis of individual mutations will confirm their potential
role in tumour progression.
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Proteasome Inhibition as a Novel Mechanism of the Proapoptotic Activity of γ-Secretase
Blocker I (GSI I) in Cutaneous T-Cell Lymphoma
MR Kamstrup, E Biskup, V Manfé and R Gniadecki Dermatology, Bispebjerg Hospital,
Copenhagen NV, Denmark
Notch signaling plays an important role in the pathogenesis of several hematologic malignancies.
We have previously discovered that Notch1 is expressed on malignant T-cells in cutaneous T-cell
lymphoma (CTCL) and is required for survival of CTCL cell lines. Notch can be inhibited by gamma-
secretase blockers (GSI), which differ widely in their ability to induce apoptosis in CTCL. The pur-
pose of the present study was to investigate whether GSI I, in addition to Notch inhibition, induces
apoptosis in CTCL by proteasome inhibition since GSI I is the most potent blocker and reveal struc-
tural similarity to the proteasome inhibitor MG-132. Cell lines derived from CTCL (MyLa, SeAx, JK,
Mac1 and Mac2a) were treated with GSI I and proteasome inhibitors (MG-132 and bortezomib).
The effects on cell viability, apoptosis and proteasome activity were measured as well as the impact
on the pro-survival nuclear factor κB (NF-κB) pathway. We demonstrate that GSI I has proteasome
blocking activity with potency comparable to proteasome inhibitors MG-132 and bortezomib in
CTCL. Proteasome inhibition is the main mechanism responsible for GSI I-induced cell death since
tiron, a compound known to reverse the effect of MG-132, restored the proteasome activity and
largely abrogated the cytotoxic effect of GSI I. Though an important mechanism of action for pro-
teasome inhibitors is inactivation of NF-κB, we demonstrate an apparent activation of NF-κB. Fur-
thermore, we show that while the tumor suppressor protein p53 is induced during proteasome
inhibition, it is dispensable for CTCL apoptosis since both SeAx cells, which harbor p53 mutations
that attenuates its apoptotic capacity and HuT-78 cells, which has a deleted p53 gene, demonstrated
potent apoptotic response. In conclusion, GSI I represents an interesting drug with dual mechanism
of action comprising Notch and proteasome inhibition.
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ATF3 – an oncogene induced by UV and CsA
PJ Dziunycz,1 K Lefort,2 S Freiberger,1 G Iotzova-Weiss,1 LE French,1 G Dotto2 and GF Hofbauer1
1 Department of Dermatology, University Hospital Zurich, Zurich, Switzerland and 2
Department of Biochemistry, University of Lausanne, Lausanne, Switzerland
SCC of the skin represents the most important cutaneous complication following solid organ trans-
plantation. This cancer develops mostly on sun-exposed areas suggesting UV radiation to be an
important factor in this process. A recent study showed the role of ATF3 - a member of the enlarged
AP1 family - in SCC development following treatment with calcineurin inhibitors such as CsA.
Increased ATF3 expression functions by suppression of p53-dependent senescence and enhances
tumorigenic potential. Still, these findings do not fully explain the preference for SCC in OTR to
appear on chronically sun-damaged skin. As UV radiation significantly contributes to SCC devel-
opment we looked at its influence on AP1 gene expression. The in-vitro experiments showed that
UVB induced expression of ATF3, c-JUN and c-FOS, while UVA selectively induced the expression
of ATF3 only. We next combined the UV irradiation with CsA treatment and found a synergistic
influence of the CsA and UVA but not UVB treatment specifically on ATF3 expression. We next
identified NRF2 as a key molecule in the UVA mediated induction of ATF3. We have shown that
induction of NRF2 induces ATF3 expression in the keratinocytes, whereas its downregulation pre-
vents the UVA mediated ATF3 expression. Furthermore we showed that NRF2 directly bind to ATF3
promoter upon UVA irradiation of keratinocytes. Our results demonstrate two mechanisms that inde-
pendently induce, and when combined together, potentiate the expression of ATF3, what may then
force the SCC development. Taking into account the previously defined role of ATF3 in the SCC
development our findings may provide an explanation and a mechanism for the often observed
burden on SCCs on sun-exposed areas of the skin in organ transplant recipients treated by calcineurin
inhibitors.
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Ellipticine induced apoptosis in cutaneous T cell lymphoma - importance of p53
C Savorani, V Manfé, E Biskup, V Pless, O Niazi and R Gniadecki Dermatology, Bispebjerg
Hospital, Copenhagen, Denmark
Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous T-cell
lymphoma (CTCL). In the advanced stages these diseases are resistant to chemotherapy and have a
grave prognosis. In this work we explored whether p53 could be a possible therapeutic target in MF
and SS. The tumor-suppressor p53 leads to cell cycle arrest and apoptosis in response to DNA dam-
age and other stress stimuli. P53 is often mutated in cancers, resulting in uninhibited proliferation
and resistance to apoptosis. Wild type p53 can be induced by the small molecule nutlin-3a, which
disrupts its binding to MDM2, causing p53 activation and apoptosis. However, mutated p53 is resist-
ant to nutlin. The aim of this project was to investigate whether mutated p53 can be activated in
CTCL with ellipticine, a novel compound shown to have a capability to rescue mutant p53 tran-
scription function. We have employed a panel of CTCL cell lines with different p53 status: SeAx (SS
cell line; mutated-p53 G245S), MyLa2000 (MF cell line, wildtype p53) and Hut-78 (leukemic CTCL,
p53 deletion). As expected and previously reported nutlin induced apoptosis and cellular senes-
cence through a p53-dependent pathway in MyLa, but not in SeAx or Hut cells. Ellipticine decreased
cell viability by 30-45% in SeAx and Myla in a time- and concentration-dependent manner reach-
ing a maximum after approx 48h (for 5 μM ellipticine). Expression of cleaved PARP by western blot
analysis verified that apoptosis was the mode of cell death. No significant effect was observed in
Hut. Combination of ellipticine with nutlin showed a synergistic activity in MyLa, but not in SeAx.
p53 expression level increased after 5 μM ellipticine both in Myla and SeAx. However, neither p21
nor Bak expression (the known p53-transcriptional targets) were seen in SeAx. Transfection of SeAx
with p53-siRNA reduced p53 but did not influence cell death. Thus, ellipticine is able to induce
apoptosis in CTCL cells with mutated p53, but the mechanism of its action is at least partially inde-
pendent of p53.
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miR214 expression and interconnected Endothelial and Smooth muscle cell Derived Neu-
ropilin-like molecule ESDN and AP-2 family protein expression in primary melanoma
M Sanlorenzo,1 S Osella-Abate,1 M Novelli,1 P Quaglino,1 F Orso,2 B Ubezio,2 F Marenco,1
M Fierro,1 M Bernengo1 and D Taverna2 1 Dermatologic Clinic, University of Turin, Turin, Italy
and 2 Molecular Biotechnology Center (MBC) University of Turin, Turin, Italy
MicroRNAs are endogenous non-coding RNAs involved in tumourigenesis. In a previous work,
miR214 was highly expressed in primary invasive melanomas and cutaneous metastases. miR214
seems to regulate AP-2α and γ as well as surface molecules involved in cell movement and adhe-
sion such as ESDN. Herein, we focused our attention on miR-214 and on transcription factors belong-
ing to the AP2 family (AP-2α and γ) and one of their major target ESDN. Patients and Methods: 67
primary melanoma (N=20 in situ, N=25 ≤ 1mm or N=22 >1 mm thick) were used to investigate
AP-2α, AP-2γ and ESDN expression using immunohistochemistry and qRT-PCR for miR214. Statis-
tical analyses were performed to identify correlations with clinico-pathological characteristics and
Disease-Free survival. Results. Median miR214 Relative expression (RE) was significantly higher in
invasive melanoma (0.36; 0,06-1.06) than “In situ melanoma” (0.01; 0,001-0.06) . Reduced ESDN
and AP-2α or γ expression (<30% melanoma cells) was found in thick melanomas compared to
thin or in situ samples. In particular, lesions with AP-2α low/AP-2γ low expression showed median
miR214 RE higher (0.35; 0,07 - 0.58) than melanoma characterised by high expression of both mark-
ers (0.016; 0,006-0.49) or only one (0.33; 0,10-1.13). The reduced expression of AP-2α, AP-2γ and
ESDN was significantly associated with unfavourable histo-pathological parameters (neo-angio-
genesis, vascular invasion and mitoses) and carried an independent role to predict shorter DFS. Con-
clusion. This study, which analyzed for the first time the simultaneous expression of mir214, AP-2α,
AP-2γ and ESDN in primary melanoma, suggests a role of miR-214 as a post-transcriptional regu-
lator of AP2 family to drive melanoma progression and identifies AP-2α, AP-2γ and ESDN as three
interconnected markers with a predictive correlation with melanoma disease course.
213
High-grade human SCC cells with epithelial-mesenchymal transition are reversed by intro-
duction of the reprogramming genes
M Takaishi,1 M Tarutani,1 J Takeda2 and S Sano1 1 Dermatology, Kochi University, Nankou, Japan
and 2 Social and Environmental Medicine, Osaka University, Suita, Japan
It was reported that induced pluripotent stem (iPS) cells from embryonic fibroblasts underwent bio-
logical and morphological mesenchymal-epithelial transition (MET). This prompted us to study
whether cancer cells under epithelial-mesenchymal transition (EMT) could be reversed by trans-
fection of the reprogramming genes. To this end, we transfected mouse-derived spindle-shaped squa-
mous cell carcinoma (SCC) cells with the reprogramming factors (Oct3/4, Sox2, Klf4, c-Myc and
Lin28), which were linked by self-cleaving peptides, through the piggyBac transposon system. Co-
transfection of the cells with the piggyBac transposon and its transposase expression vectors resulted
in generation of stable transformants, which demonstrated a polygonal morphology with well-estab-
lished cell-cell adhesion. Quantitative RT-PCR and immunoblotting revealed increased epithelial-
associated molecules and reduced mesenchymal molecules in the transformed cells, while the
parental spindle SCC cells showed more ‘mesenchyamal’. Furthermore, cell proliferation and inva-
sion activity in vitro were reduced in the transformed cells. We also introduced the reprogramming
factors into high-grade human SCC lines, which showed spindle-shape morphology. Like mouse
SCC cells, the transformants from human SCC cells showed more epithelial features in morphology
than the parental cells. Immunoblotting revealed that keratins and E-cadherin were up-regulated in
the transformed cells. Also, cell invasion activity in vitro was significantly attenuated in the trans-
formed cells. Taken collectively, these results suggested that introduction of the reprogramming fac-
tors used for iPS lead to reversal of biological and morphological malignant nature associated with
EMT. Understanding of the molecular mechanisms underlying MET induction by the reprogram-
ming genes may provide a clue for novel anti-cancer therapy.
214
A Molecular Signature Characteristic for Tumor-Stage Mycosis Fungoides
MS van Kester, WY Leung, MK Borg, WH Zoutman, JJ Out-Luiting, PM Jansen, MH Vermeer,
R Willemze, R van Doorn and CP Tensen Dermatology, Leiden University Medical Centre,
Leiden, Netherlands
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma. To iden-
tify a molecular signature characteristic for MF tumor stage, we used RNA deep sequence and micro
array-based analyses of tumor skin biopsies and integrated this information with publicly available
data sets. Results were further refined and validated by quantitative PCR for a selection of tran-
scripts in additional patient samples and relevant controls. Comparison of the MF tumor gene expres-
sion pattern with normal skin, inflamed skin and T-cell (sub set)s revealed a signature that is in agree-
ment with the highly proliferative character of this T-cell malignancy, showing altered expression of
many cell cycle and kinetochore regulators. In this manner we also uncovered novel details of the
immunophenotype of the tumor cells, which, in contrast to the proposed Th2 phenotype appears
to be dominated by the cytokines IL-10, IL-26 and IL-32, the chemokines CCL18, CXCL9, 10, 11
and up-regulation of the chemokine receptors CCR1 and 7. In addition we identified possible ther-
apeutic targets (RRM2, IDO1, TOP2A), novel diagnostic markers (amongst others GTSF1 and TRIP13)
and expression of a set of novel long non-coding RNAs. The signature indicated loss of expression
of the NF-kB inhibitor, NFKBIZ, which may, in part, explain the enhanced activity of NF-kB a hall-
mark of MF. In sum, the approach provided more insights into the pathogenesis of this lymphoma,
a description of its (immuno) phenotype, and the discovery of previously unreported putative diag-
nostic markers and therapeutic targets.
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Th1-Cytokine-induced stabilization of Retinoblastoma protein (Rb)-mediated cell cycle con-
trol
K Braungart, M Hahn, S Fischer, H Braumüller, E Brenner, S Weidemann, T Wieder and M Röcken
Department Of Dermatology, University Medical Center, Tübingen, Germany
RIP1-Tag2 mice expressing the T antigen 2 (Tag2) under control of the rat insulin promoter (RIP)
undergo multistage carcinogenesis and develop neuroendocrine β-cell cancers. Cancer progression
originates from Tag-induced inactivation of p53 and incomplete inhibition of the p16Ink4a/Rb path-
way leading to disruption of effective cell cycle control. Interestingly, we found prolonged survival
of RIP1-Tag2 mice and reduced β-cancer cell proliferation by treatment with Tag-specific, interferon-
γ (IFNγ)- and tumor necrosis factor (TNF)-producing T helper 1 (Th1) cells. As MHC class II-restricted
Th1 cells should not directly interact with β-cancer cells, we focussed our research on the soluble
Th1 cytokines IFN-γ and TNF and investigated their direct influence on freshly isolated β-cancer
cells. We analyzed the effects of IFNγ and TNF on proliferation and cell cycle control of β-cancer
cells in vitro. Proliferation was measured by BrdU incorporation and cell cycle analysis by flow
cytometry. In addition, the p16Ink4a/Rb pathway was analyzed by Western blot. When treated for 72
h with IFNγ or TNF, β-cancer cells showed a significant decrease in proliferation by 63% and 27%,
respectively. FACS analysis revealed that the cytokines arrested the β-cancer cells in the G0/G1
phase of the cell cycle indicating an activation of the p16Ink4a/Rb signalling pathway. Interestingly,
we saw an upregulation of p16Ink4a after cytokine treatment. This upregulation caused severe
hypophosphorylation of Rb at Ser795 thereby stabilizing Rb-mediated cell cycle control. To demon-
strate a direct link between Rb stabilization and cell cycle control in β-cancer cells, we silenced Rb
by lentiviral infection with shRNA. First results showed that, indeed, downregulation of Rb enhanced
β-cancer cell proliferation. Taken together, our data show that pro-inflammatory cytokines stabilize
Rb-mediated cell cycle control of cancer cells, and strongly suggest that this significantly contributes
to tumor surveillance by the immune system.
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Influence of transcription, repair, and three-dimensional genome organization on muta-
tional hotspots in skin cancers
C Ho2 and C Zheng1 1 Spatial Biology, OHSU, Portland, OR and 2 Statistics, UC Berkeley,
Berkeley, CA
Although an increasing number of cancer exomes and genomes have been sequenced for somatic
aberrations, most of existing studies and associated models assume a random distribution of muta-
tion in deducing candidate driver or tumor suppressor mutations. Inspecting whole-genome DNA
sequence from squamous cell carcinomas and melanomas of the skin, we noted a reproducible,
stereotyped density of somatic mutations in cancer genomes. Examining a broad range of other solid
cancers, we found that this stereotyped pattern appeared to be a consistent feature of cancer genomes,
substantially influencing interpretation of recurrent mutations in cancer genomes. Using statistical
variance analysis of these data, we discovered that transcription and long-range physical associa-
tions in genome organization each play a major determinative role in mutational accretion, reveal-
ing critical determinants of gene mutation frequency in individual cancers. These associations,
both both determinants achieving a P-value < 0.02, substantially change the interpretation of recur-
rent mutation prevalence in human cancers. We also present evidence for the role a position-depend-
ent deficiency in DNA repair responsible for a significant portion of these findings.
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Establishing a murine xenograft model and an irradiation technique for investigating the radio-
therapy sensitivity of squamous cell carcinoma tumors
R Hojatpanah,1 N Suchowerska,2 G Halliday1 and JG Lyons3 1 Dermatology, Bosch
Institute,Sydney Medical School,The University of Sydney, Camperdown, Sydney, NSW,
Australia, 2 Department of Radiation Oncology,, Royal Prince Alfred Hospital, Sydney, NSW,
Australia and 3 Sydney Head and Neck Cancer Institute, Sydney Cancer Centre, Royal Prince
Alfred Hospital, Sydney, NSW, Australia
The purpose of this study was to develop an animal xenograft model and an irradiation technique
similar to that used for human squamous cell carcinoma (SCC) treatment. SCC of the skin and the
head and neck mucosae are highly prevalent, potentially causing severe disfigurement or death of
the patient. SCC arises from keratinocytes, the cells that line the skin and the oral cavity. Radio-
therapy is commonly used to treat SCCs, but often with limited success. To establish a murine model
6 different SCC cell-lines (HN13, SCC15, SCC25, UM-SCC4, A431 and BIRC22) were injected to
two different strains of immunodeficient mice. HN13 cell-line needed to be stably transfected by
the Hras(G12V) oncogene in order to form tumor. When tumors reach a volume of 0.25ml (8mm
diameter), radiotherapy was administered, delivering 2Gy daily fractions for 25 days, using a clin-
ical 6MV photon radiation beam produced by Varian Novalis linear accelerator. A novel apparatus
was designed for the irradiation of mice enabling the mice to be easily and reproducibly irradiated.
Tumor size reduction was measured following irradiation using a Carestream bio-imager and calipers.
After a total dose of 50Gy, the response to irradiation was evident in tumor shrinkage of 96% (HN13),
94% (SCC15), 81%(SCC25) and 90%(BIRC22). Thus, we have established an animal xenograft model
and a novel irradiation technique similar to that used for cancer patient treatment that can be used
to investigate in-vivo the effects of specific cancer-related genes and drugs in the radiosensitivity of
SCCs.
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Knockdown of collagen XVII or β4-integrin by RNAi impairs the adhesion, migration and inva-
sion of SCC cells
J Moilanen,1 S Löffek,3 N Kokkonen,1 S Salo,4 T Hurskainen,1 T Salo,4 A Manninen,2 C Franzke,3
L Bruckner-Tuderman3 and K Tasanen1 1 Dermatology, University of Oulu and Clinical Research
Center, Oulu University Hospital, Oulu, Finland, 2 Biocenter Oulu, University of Oulu, Oulu,
Finland, 3 Dermatology, University Medical Center Freiburg, Freiburg, Germany and 4
Diagnostics and Oral Medicine, University of Oulu, Oulu, Finland
Our study aims at clarifying the function of two hemidesmosomal constituents, collagen XVII and
β4-integrin (ITGB4) in the adhesion and migration of squamous cell carcinoma (SCC) cells. We have
created collagen XVII and ITGB4 knockdown cell lines for SCC-25 and HSC-3 (human oral squa-
mous cell carcinoma) cells by using viral RNA interference. Morphological changes in knockdown
cell lines were studied with confocal microscopy. Adhesion of knockdown cells was analyzed by
performing electric cell substrate impedance sensing (ECIS) assay and by traditional cell counting
assay utilizing water-soluble tetrazolium salt (WST-8). To study if the knockdown has an effect on
migration of the cells we performed traditional scratch assay for wound healing analysis and fol-
lowed single cell motility by live-cell time lapse imaging. Invasion studies were performed using an
organotypic myoma model. Both collagen XVII and ITGB4 knockdown led to dramatic changes in
the morphology and behavior of SCC-25 cells. The cells lacking collagen XVII or ITBG4 were small
and round compared to the flat and widespread mock-transfected control cells. Also the adhesion
of cells was notably disturbed. The movement of the SCC-25 knockdown cells was stationary rotat-
ing and they were unable to close the wound. Interestingly, both of the RNAi cells lost their ability
to invade to the myoma tissue almost completely. In the more aggressive SCC cell line, HSC-3, col-
lagen XVII knockdown affected the behavior of the cells in a much more refined way and the mor-
phology stayed unchanged. Taken together our data clearly demonstrates the involvement of both
collagen XVII and ITGB4 in the pathogenesis of certain types of SCCs since the absence of these
proteins leads to non-migrating and non-invading SCC-25 cells.
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Pituitary tumour transforming gene 1 has a critical role in epidermal carcinogenesis
Y Ishitsuka, Y Kawachi, H Maruyama, Y Fujisawa, S Taguchi, J Furuta, Y Nakamura, Y Ishii and
F Otsuka Department of Dermatology, Graduate School of Comprehensive Human Sciences,
University of Tsukuba, Tsukuba, Japan
The epidermis is a self-renewing tissue homeostasis of which is dependent upon the tight regula-
tion of proliferation and differentiation by numerous factors. When the balance leans toward pro-
liferation and differentiation is suppressed, epidermal proliferative disorders occur, such as squa-
mous cell carcinoma (SCC) and psoriasis. Pituitary tumor transforming gene 1 (PTTG1) is a ubiquitous
and multifunctional transcription factor whose functions in cellular growth, tumorigenesis, or abun-
dance in multiple cancer cell types are known. These evidences imply a significance to investigate
its less known but important roles in epidermal physiology or pathology. Keratinocytes were cul-
tured under 2D or 3D conditions with constitutive overexpression of PTTG1, and alterations of
PTTG1 expression in SCC and its precursors were analyzed by immunohistochemical or immuno-
fluorescent method. Human keratinocytes overexpressing PTTG1 formed thicker epidermid epithe-
lia under 3-D conditions with suppression of early differentiation, whereas calcium-induced dif-
ferentiation was retarded by excess PTTG1 in neonatal murine keratinocytes under 2-D conditions.
In addition, cyclin B1, CDK1, and c-Myc, were upregulated in the keratinocytes both at the mRNA
and protein levels. In contrast, depletion of PTTG1 caused their downregulation and constrained
proliferation with retention of differentiation capacity. On the other hand, the epidermal prolifera-
tive disorders showed salient PTTG1 expression with concomitant expression enhancement of Ki67,
cyclinB1, c-Myc and p53 according to malignant progression. These findings suggest that PTTG1
can alter the proliferation status by modulating the expression levels of the other factors closely
related with cellular growth. Furthermore, these molecular pathways and altered PTTG1 expres-
sion in the epidermal hyperproliferative disorders explain important roles of PTTG1 in epidermal
carcinogenesis and malignant progression.
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5-hydroxymethylcytosine regulation in aging skin and malignant melanoma
H Fujiwara and M Ito Dermatology, Niigata-University, Niigata, Japan
DNA methylation down-regulates mRNA transcription by 5-methylcytosine (5-mC) in promoter
sequence, and takes significant roles in development, aging, and carcinogesis. Recently the exis-
tence of 5-hydroxymethylcytosine (5-hmC) in human genome was discovered, and made confu-
sion in epigenetic researchers. Its function in genome was considered to be totally different from 5-
mC, and almost all the existed methods for analyzing DNA methylation can not differentiate 5-mC
from 5-hmC; thus all the data collected on 5-mC analyses require reevaluation. We established
new method, non-isotopic cytosine extension assay (NICEA) for 5-hmC, which disclose amount of
global, CpG-specific 5-hmC, based on NICEA we developed previously. With NICEA for 5-hmC and
glucMS-PCR we studied genomic 5-hmC amount in normal skin and peripheral lymphocytes in var-
ious ages. 5-hmC in malignant melanoma and nevocellular nevus was also studied. With NICEA
for 5-hmC, 5-hmC amount did not show significant change in various ages, both in the skin and
peripheral lymphocytes; the 5-hmC amount in the skin and peripheral lymphocytes was also com-
parable. Interestingly malignant melanoma showed significantly larger amount of 5-hmC than nevo-
cellular nevus. With glucMS-PCR, which reveals 5-hmC existence in a small fragment, e.g. 100bp
long, of specific sequence, we analyzed 5-hmC of RASSF1 promoter. GlucMS-PCR did not reveal
significant change in various ages, both in the skin and peripheral lymphocytes in RASSF1 promoter,
although in detail analysis, sun-exposed skin of the middle age revealed less 5-hmC; sun-exposed
skin in general revealed less 5-hmC than non-exposed skin. Malignant melanoma showed compa-
rable amount of 5-hmC to nevocellular nevus in RASSSF1 promoter. In conclusion 5-hmC amount
was well-conserved in normal skin and peripheral lymphocytes in various ages; unknown mecha-
nism should be regulating 5-hmC in global genome. In some specific conditions, such as in malig-
nant melanoma, the regulation might be disturbed, resulted in the alteration of protein expression.
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Mast Cell Derived Mediator Chymase as a Potent Regulator of uPA/ uPAR System in Cuta-
neous Tumors
M Artuc,1 S Guhl,1 M Babina,1 U Steckelings2 and T Zuberbier1 1 Dermatology, Charité-
Universitätsmedizin Berlin, Berlin, Germany and 2 CCR, Charité-Universitätsmedizin Berlin,
Berlin, Germany
Reorganisations of the cytoskeleton of tumor cells, adherence to adjacent cells and to the surrounding
extracellular matrix (ECM) and degradation of ECM are cellular processes which determine tumor
invasion and metastasis. The urokinase (uPA) mediated plasminogen activation system is involved
in all these events. The central molecule of this system, the uPA receptor (uPAR), is able to regulate
the proteolytic activity of its ligand on the cell surface and the integrin mediated cell adhesion to
ECM. Several immunohistochemical studies indicated that mast cells (MC) are present in increased
number in tumor-stroma and may be involved in the regulation of tumor progression. In this con-
text, we were interested to study, how mast cells regulate the uPA/uPAR system in cutaneous tumors.
Cutaneous tumor cell lines derived from melanoma or squameous cell carcinoma (SCC) were cul-
tivated for 24 h with or without conditioned medium derived from IgE-activated or non-activated
primary dermal mast cells. Protein expression of uPA and uPAR was estimated by ELISA in super-
natants of each individual cell line. SCC cells constitutively released uPA (SCC-12 10ng/ml, SCC-
13 20ng/ml). However stimulation with conditioned medium inhibited the release of uPA. Pre-incu-
bation of the supernatants with chymase inhibitor SBTI but not with tryptase inhibitor aprotinin
restored the level of uPA to control levels. Stimulation of SCC and melanoma cell lines with con-
ditioned medium led to a strong and significant increase in uPAR release (in SCC-12 cells from
50pg/ml to 1700 pg/ml, in SCC-13 from 50pg/ml to3800 pg/ml in mel-5 from 800pg/ml to 2500
pg/ml and in mel-6 from 500 pg/ml to 2000 pg/ml), which was significantly attenuated by the chy-
mase inhibitor SBTI but not of the tryptase inhibitor aprotinin. This result suggests that mast cell
derived mediators, in particular chymase, may be major inducers of uPAR release from SCC and
melanoma cells, thus modulating tumor invasion and metastasis.
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DeltaNp63alpha drives mutagen-induced skin tumor initiation and progression to malignancy
M Devos,1 G Denecker,1 S Lippens,1 B Gilbert,1 K Leurs,1 T Hochepied,1 H van Bokhoven,2
J Haigh,1 P Vandenabeele1 and W Declercq1 1 DMBR, VIB-Ghent University, Ghent, Belgium
and 2 Department of human Genetics, Radboud University, Nijmegen, Netherlands
P63 is a transcription factor crucial for ectodermal development and the formation of stratifying
epithelia. Unlike its family member p53, the p63 gene is rarely mutated in human cancers, but it is
often overexpressed. This suggests an important role for p63 in cancer development. Squamous
Cell Carcinoma (SCC) is a common and treatment-refractory form of human cancer in epithelial tis-
sues were the p63 locus is frequently targeted for genomic amplification, leading to increased lev-
els of the deltaNp63alpha isoform. To investigate the contribution of deltaNp63alpha in the pro-
motion and progression of SCC, we developed K5-Cre/LoxP-controlled ROSA26 promotor-driven
deltaNp63alpha conditional transgenic mice. These mice develop epidermal hyperplasia and hair
abnormalities, eventually leading to alopecia, and show higher morbidity upon aging. Interest-
ingly, spontaneous benign tumors occur in 25% of the transgenic mice. When subjected to two dif-
ferent models of chemical carcinogenesis (DMBA/TPA and DMBA/DMBA), we found that
deltaNp63alpha transgenic mice were more prone to the onset of tumor formation, and display
more and bigger tumors compared to control mice and this in a gene dosage-dependent manner.
Moreover, progression to malignant carcinoma was only observed in the deltaNp63alpha transgenic
lines. These results clearly show a causal relationship between p63 gene amplification and SCC
development. We could show that in vitro deltaNp63alpha transgenic primary keratinocytes sur-
vive longer than control primary keratinocytes. Currently we are further analyzing which processes
are altered and which genes are deregulated in the transgenic keratinocytes.
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The role of the TRAF-interacting protein (TRAIP) in the regulation of cellular proliferation
C Chapard, D Hohl and M Huber Dermatology, CHUV, Lausanne, Switzerland
Christophe Chapard, Daniel Hohl, Marcel Huber Dermatology, University Hospital, Lausanne,
Switzerland. Ubiquitination is a post-translational protein modification affecting proliferation, dif-
ferentiation, apoptosis, or inflammation. Ubiquitin addition to proteins is carried out by the sequen-
tial action of 3 enzymes: E1-activating enzyme, E2-conjugating enzyme, and E3 ubiquitin ligase.
TRAIP (TRAF-interacting protein) is a ubiquitously expressed E3 ligase. Elimination of TRAIP expres-
sion in embryonic development by mutations or knock-out either in Drosophila or mice lead to a
lethal phenotype due to abrogation of cell proliferation and increased apoptosis. Furthermore, knock-
down of TRAIP in normal human epidermal keratinocytes repressed cell proliferation and blocked
the cell cycle in G1/S. These results corroborate an important role of TRAIP in regulating cell pro-
liferation. To investigate the cellular localization of TRAIP, lentiviral vectors were constructed driv-
ing CMV promoter-based expression of a GFP fusion protein of TRAIP (TRAIP-GFP) and GFP. Trans-
duction of HeLa cells with TRAIP-GFP followed by immuno-fluorescence analysis demonstrated
that TRAIP-GFP is localized to the nucleolus during interphase. TRAIP1-289 or TRAIP289-469 GFP
fusion proteins expressed in HeLa cells localized to the cytosol or the nucleus, respectively, indi-
cating that the N-terminal part specifies nucleolar localization whereas the C-terminal region
determines nuclear transfer. Inspection of the primary TRAIP protein sequence did not reveal any
motives commonly known to be involved in nuclear or nucleolar transfer. In stably transduced HeLa
cells the expression of TRAIP-GFP protein was significantly lower than the GFP protein level although
the mRNA levels were comparable. Determination of the half-life using the protein synthesis inhibitor
cycloheximide showed that TRAIP has a half-life of 3.2±1.2 hours (n=5) suggesting that it is an unsta-
ble protein. These results indicate that the level and subcellular localization of TRAIP protein is
highly regulated which might be important in cell cycle control.
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Expression of activated NOTCH1 induces terminal differentiation in squamous cell carcinoma
keratinocytes
KS Robinson,1 KJ Purdie,4 RJ Cho,3 JC Aster,2 IM Leigh1 and AP South1 1 Division of Cancer
Research, University of Dundee, Dundee, United Kingdom, 2 Department of Pathology,
Brigham and Woman’s Hospital, Boston, MA, 3 Department of Dermatology, University of
California, San Francisco, CA and 4 Barts and the London School of Medicine, University of
London, London, United Kingdom
Loss of function mutations in NOTCH receptors have been reported in 75% of cutaneous Squamous
Cell Carcinomas (SCC) and a significant proportion of Head and Neck SCC. We have isolated and
established three NOTCH1 null SCC lines which provide an ideal platform to interrogate NOTCH
signaling in this tumour type. Using retroviral constructs expressing intracellular NOTCH (ICN)
under the control of the gamma-Secretase complex, we show that no viable NOTCH1 null SCC
keratinocytes are recovered after successive rounds of transduction and antibiotic selection unless
such transduction and selection were undertaken in the presence of the gamma-Secretase inhibitor
(GSI) XXI (two SCC lines; n=1 and 2 respectively). Using SCCIC15, a genital SCC line, we show that
washout of GSI (leading to ICN1 activation) results in a gradual slowing of mitochondrial dehydro-
genase activity over 7 days and an induction of Keratin 10 expression as early as 24 hours suggest-
ing that ICN1 activation triggers terminal differentiation in SCC keratinocytes. In addition to these
experiments exome level sequencing identifies mutations in NOTCH receptors (N1-4) in 70% well
differentiated cutaneous SCC tumours (total of 14 independent mutations in 7 tumours) compared
with 100% of poorly differentiated cSCC tumours (total of 28 independent mutations in 10 tumours).
This difference is most apparent for NOTCH2 (20% of tumours and 3 mutations verses 70% of
tumours and 12 mutations) supporting previously reported murine data indicating a role for Notch
in SCC progression. Overall, our results are consistent with a model in which NOTCH loss-of-func-
tion contributes to oncogenesis by suppressing terminal differentiation, and suggest that reactiva-
tion of NOTCH target gene expression is a rational approach to SCC therapy.
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Sézary syndrome and mycosis fungoides show differential expression of programmed death-
1
F Çetinözman,1 PM Jansen,2 MH Vermeer1 and R Willemze1 1 Dermatology, Leiden University
Medical Center, Leiden, Netherlands and 2 Pathology, Leiden University Medical Center,
Leiden, Netherlands
Neoplastic T cells of some types of malignant T-cell lymphoma, including mycosis fungoides (MF)
and Sézary syndrome (SS), have been reported to express programmed death-1 (PD-1). However,
published observations are not consistent and sometimes conflicting. This study was aimed to
investigate the expression of PD-1 in the skin of a large number of SS and MF, in order to determine
whether PD-1 is differentially expressed. We performed PD-1 staining on formalin-fixed, paraffin-
embedded skin biopsies from 27 patients with SS and 60 patients with MF. In order to find out a
possible relationship with follicular helper T cells, PD-1 positive cases were additionally stained
with antibodies against BCL6, CXCL13 and CD10. We observed that PD-1 was expressed by more
than 50% of the neoplastic T cells in 24 of 27 (89%) cases of SS. In contrast, PD-1 expression by
more than 50% of neoplastic T cells was found in only 8 of 60 (13%) MF patients, including only
1 of 8 (12%) patients with erythrodermic MF (E-MF). Additional stainings on serial skin sections from
PD-1 positive cases showed that CXCL13 and BCL6 generally stained 25–50% of the PD-1+ cells,
while expression of CD10 was uncommon. Our study clearly demonstrates that SS and (E-) MF
exhibit differential expression of PD-1, and furthermore, supports the opinion that SS and MF are
distinct entities.
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Comparison of immunosuppressive cells and immunomodulatory cells in kerartoacanthoma
and cutaneous squamous cell carcinoma
Y Kambayashi, T Fujimura and S Aiba Department of Dermatology, Tohoku University
Graduate School of Medicine, Sendai, Japan
The imbalance of immunosuppressive cells and immunomodulatory cells plays one of the most
important roles in inhibiting the antitumor immune response of the tumor-bearing host. Among such
cells, regulatory T cells (Tregs), together with immunosuppressive macrophages, such as CD163+
M2 macrophages, play roles in maintaining tumor microenvironment. In contrast, IL-27 induces
STAT1 and STAT3 activation, thus resulting in the enhancement of naive CD4 T-cell proliferation,
the promotion of early Th1 differentiation, and the induction of the antitumor immune response.
The purpose of this study was to elucidate the involvement of immunosuppressive cells, such as
Tregs and CD163+ macrophages, as well as immunomodulatory cells (i.e. IL-27 producing cells)
in keratoacanthoma (KA) and invasive squamous cell carcinoma (SCC). We immunohistologically
examined the presence of CD3+ Foxp3+ Tregs, CD163+ M2 macrophages and MMP-9+ cells as
well as IL-27 producing cells in fixed sections of lesional skin from 10 patients with KA and 18
patients with SCC. Increased numbers of CD3+ Foxp3+ Tregs were observed in SCC compared to
KA (31.4± 9.2% vs 12.8± 6.2%). In parallel with Tregs, higher numbers of CD163+ macrophages
were detected in SCC (266.7±23.7 vs 105.7± 25). In contrast to immunosuppressive cells, IL-27 pro-
ducing cells were increased in KA (10.7± 3.8 vs 94.7± 16). In addition, the expression of pSTAT1
on tumor cells was observed only in KA. These findings suggest that the induction of immunosup-
pressive cells and immunomodulatory cells differs between KA and SCC, which might explain the
spontaneous regression in KA.
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MCIR variants associated with BCC risk in a Southern European population
C Dessinioti,1 V Sypsa,2 G Dimisianos,2 K Kypreou,1 E Kodela,1 O Papadopoulos,3 V Chasapi,1
C Antoniou1 and AJ Stratigos1 1 Oncology Unit, Department of Dermatology, Andreas Sygros
Hospital, Athens, Greece, 2 Department of Hygiene, Epidemiology and Medical Statistics,
Athens University Medical School, Athens, Greece and 3 Department of Plastic Surgery,
Andreas Sygros Hospital, Athens, Greece
Basal cell carcinoma (BCC) incidence is increasing, however phenotype-genotype interaction stud-
ies in darker pigment phenotypes are limited. In order to assess the association of BCC with MC1R
variants and pigmentary characteristics, we conducted a hospital-based case-control study in a
Southern European Greek population. BCC patients and controls were examined for pigmentary
traits and the presence of lentigines, and blood was collected for PCR. The whole coding sequence
of the MC1R gene was amplified and sequencing was carried out. A total of 141 patients and 166
controls were included in the analysis. Among pigmentary characteristics in controls, the presence
of MC1R polymorphisms was associated only with hair color (p<0.001). Among non-synonymous
MC1R variants, BCC was associated with R160W (OR:4.3, 95% CI:1.31-13.8, P=0.016) and R163Q
(OR:5.0, 95% CI: 1.56-15.81, p=0.007). Analysis of MC1R genotype, after adjustment for age, skin
color, phototype, eye and hair color, and the presence of lentigines, showed increased BCC risk
associated with the presence of 2 or more MC1R variants (OR: 3.07, 95% CI: 1.13-8.34, p=0.028),
and in particular 2 or more major variants (OR: 7.15, 95% CI: 1.27-5.52, p=0.019). Subgroup analy-
sis for early onset BCC (< 50 years old) did not reveal any significant association with the presence
of any MC1R polymorphism, or with the type (major or minor function) or number of MC1R vari-
ants (p>0.05). In conclusion, MC1R variants were associated with increased BCC risk in a South-
ern European Greek population, with R160W and R163Q being the most strongly correlated non-
synonymous polymorphisms.
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Fc gamma receptor II (CD32) as novel regulator of keratinocyte proliferation and differenti-
ation
SN Freiberger, PJ Dziunycz, G Iotzova-Weiss, LE French and GF Hofbauer Department of
Dermatology, University Hospital Zurich, Zurich, Switzerland
Proliferation and differentiation are two major steps in keratinocyte maturation. During this matu-
ration process keratinocytes stop proliferating and start differentiating. Several features lead to abnor-
mal proliferation of keratinocytes, promoting tumorigenesis including skin squamous cell carcinoma
(SCC). Fc gamma receptor II (CD32) is commonly expressed on immune cells but was recently found
on keratinocytes as well. However, the function of this receptor on keratinocytes is completely
unknown. In this study, we investigated the protein level of CD32 isoforms A, B and C on primary
human keratinocytes of different donors and on SCC cells by Western Blotting and immunohisto-
chemistry. Furthermore, we performed blocking experiments using a specific antibody for CD32
and measured proliferation by BrdU incorporation. Also, we analyzed receptor activation of CD32B
upon challenging cells with either blocking antibody or the known ligand of CD32, IgG. We found
CD32 isoforms A, B and C differentially expressed on primary human keratinocytes and the squa-
mous cell carcinoma cell line SCC13. Additionally, we found differences in the protein expression
of CD32 isoforms when comparing growing and differentiated cells. Immunohistochemical stain-
ing of healthy human skin, well differentiated and poorly differentiated SCC with CD32B shows a
more prominent staining in less differentiated tumor cells compared to well differentiated cells,
while normal skin is weakly immunoreactive, suggesting CD32 to participate in the process of dif-
ferentiation in keratinocytes. Blocking of CD32 with a specific antibody leads to a highly increased
proliferation of primary human keratinocytes while it has no effect on SCC13 cells. Our data pro-
vide evidence for CD32 playing a role in differentiation and proliferation of keratinocytes suggest-
ing it as a novel target for cancer therapy.
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Versican as regulator of skin homing of Sézary cells
MB Karpova,1 K Fujii,2 O Georgiev,3 R Dummer1 and M Urosevic-Maiwald1 1 Department of
Dermatology, University Hospital of Zürich, Zürich, Switzerland, 2 Department of
Dermatology, Okayama University Graduate School of Medicine, Okayama, Japan and 3
Institute of Molecular Biology, University of Zürich, Zürich, Switzerland
Cutaneous T-cell lymphomas (CTCLs) are the most common subtype of primary cutaneous lym-
phomas, representing two thirds of all cases. This group of diseases is characterized by the accu-
mulation of malignant CD4+ T-cells showing a memory phenotype in the skin. Most studied enti-
ties in this group are mycosis fungoides (MF) and the leukemic form, Sézary syndrome (SS). SS is
characterized by erythroderma, lymphadenopathy and the presence of neoplastic T lymphocytes,
so called Sézary cells (SéCs) in the blood. In this study we used gene expression profiling on CD4+
SéCs, which were additionally sorted according to patient-specific TCR-Vβ expression (Vβ+). The
comparison of clonal CD4+ T cells (Vβ+) from patients and non-clonal CD4+ T cells obtained from
the same patient (Vβ-) was done. Validation experiments of a candidate gene effects were performed
on CD4+Vβ+ SéCs freshly sorted from patients and using established cutaneous lymphoma cell
lines (SeAx, MyLa, and Hut78). Versican, a gene encoding large chondroitin-sulphate proteoglycan,
was the highest up-regulated gene in clonal CD4+Vβ+ SéCs in our microarray analysis. Versican
has four isoforms (V0-V3) that are produces by alternative splicing. Expression pattern revealed pref-
erential expression of Versican V1 isoform in the sorted SéCs from patients and also in the cutaneous
lymphoma cell lines. Versican expression was influenced by various cytokines in a different man-
ner. Fluctuations in Versican expression affected the motility and migration potential of cutaneous
lymphoma cell lines towards cytokines and chemokine’s. We could show that Versican V1 expres-
sion may modulate the skin homing of SéCs. Our experiments suggest a new factor that may regu-
late skin homing of SéC and we continue to work on this topic.
S40 Journal of Investigative Dermatology (2012), Volume 132
ESDR12_Abstracts-3  7/20/12  1:26 PM  Page S40
Carcinogenesis and Cancer Genetics | ABSTRACTS
230
Topical application of a film-forming medical device containing photolyase and UV filters in
actinic keratoses: role of CPI-17 gene
J Puig-Butille,1 M Potrony,1 C Badenas,1 J Malvehy,2 C Trullas,3 F Garcia-García,4 J Dopazo4 and
S Puig2 1 Melanoma Unit, Biochemistry and Molecular Genetics Service, Hospital Clinic of
Barcelona, IDIBAPS, CIBER de Enfermedades Raras-Instituto de Salud Carlos III, Barcelona,
Spain, 2 Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS,
CIBER de Enfermedades Raras-Instituto de Salud Carlos III, Barcelona, Spain, 3 ISDIN,
Barcelona, Spain and 4 Department of Bioinformatics-Functional Genomics Node, National
Institute of Bioinformatics, CIPF, CIBER de Enfermedades Raras-Instituto de Salud Carlos III,
Valencia, Spain
Actinic keratoses (AK) are precancerigenous lesions which are caused in part by the carcinogenic
effect of the UV genotoxic photoproducts cyclobutane pyrimidine dimmers CPD and 6-4 photo-
products (6-4PPs). Photoreactivation is a repair mechanism carried out by photolyases which specif-
ically recognize and repair either CPDs or 6-4PPs. Beneficial effect of such enzyme into AK treat-
ment has been recenty postulated. The aim of the study was to analyze the molecular effect of
photolyase in 7 AK patients by expression array approach and bioinformatics methods. Skin recov-
ery after treatment was confirmed in all patients by histopathological and molecular data which
found overrepresentation of genes with biological functions involved in cell-cell communication,
cell adhesion and homeostasis. The AK response was associated to overexpression of CPI-17 gene
and determined by the initial expression level of the gene (P-value=0.001). Low levels of CPI-17
were directly associated to proinflamatory genes such as TNF (P-value=0.012) and IL-1B (P-
value=0.07). Gene set analysis found that skin recovery was associated to biological process involved
in tissue homeostasis and cell maintenance. This study suggests a role of CPI-17 gene in reconsti-
tution of skin homeostasis in AK lesions.
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Mitotic catastrophe is implicated in the resistance of basal carcinoma cells to photodynamic
therapy
A Juarranz,1 Y Gilaberte,2 A Damian,1 E Carrasco,1 S Lucena,1 M Calvo,1 I Dias-Almeida1 and
A Zamarrón1 1 Biology, Universidad Autonoma of Madrid, Madrid, Spain and 2 Hospital San
Jorge, Huesca, Spain
Basal cell carcinomas (BCC) are frequently observed in white population. Many of them arise as a
consequence of a constitutive activation of Sonic Hedgehog pathway due to mutations in the PTCH
gene, although other DNA alterations should be also considered. Photodynamic Therapy (PDT) with
methyl-aminolevulinic acid (MAL) offers excellent results in the treatment of BCC. MAL, acts as a
precursor of protoporphyrin IX (PpIX) and accumulates, in tumors tissues. Subsequent irradiation
with visible light generates reactive oxygen species, which are responsible of tumoral cell death.
However, as it happens in other cancer therapies, PTD is not always effective. Therefore, it is nec-
essary to characterize the BCC response to MAL-PDT in order to optimize it or, eventually, to com-
bine it with other therapies to completely remove the tumour. We have compared the response to
MAL-PDT on a human BCC cell line obtained from a tumor located in the face and a cell line
obtained from BCC induced by chronic UV-irradiation in a ptch+/- mice (AJ57); the histology per-
formed before the stablisment of the cell culture confirmed that the induced tumors were BCC . We
demonstrate that murine cell lines are more sensitive to PDT than the human BCC cells. Lethal
conditions for AJ57 (85%) caused death mainly by necrosis. On the opposite, the same conditions
induced 50% cell death in the human line. In this case, we identified disorganization of micro-
tubules, increased number of cells in division with altered spindles, heterogeneity both in cell and
nucleus size and multinucleated cells. Cell cycle analysis by flow cytometry confirmed the increased
number of cells in G2-M and polyploidy 24 and 48 hours after PDT. In parallel, TUNEL assay revealed
a high number of cells in apoptosis. These results indicate that PDT caused mitotic catastrophe in
BCC human cell line followed, mainly, by apoptosis with DNA disposed in the metaphase plate.
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Genetic Susceptibility In Familial And Multiple Melanoma Patients In Central Italy
M Fargnoli, C Pellegrini, D Kostaki, M Suppa, A Piccioni, A Antonini and K Peris Department of
Dermatology, University of L’Aquila, L’Aquila, Italy
Inherited melanoma susceptibility genes can be stratified by risk profile into high-penetrance genes
and low-penetrance alleles. High-penetrance factors are expressed in familial clustering of melanoma
and include mutations in CDKN2A andCDK4. In addition to high-penetrance genes, variants in the
MC1R gene, one of the major determinants of hair and skin pigmentation, have been classified as
‘low-risk’ melanoma susceptibility alleles. Recently, the MITF gene has been identified as a novel
melanoma-predisposing gene with the E318K variant defined as an intermediate risk variant. To
determine the contribution of these candidate genes to melanoma genetic predisposition in patients
from central Italy, we recruited 52 familial melanoma (FM) patients from 34 kindreds with at least
two documented cases and 20 sporadic multiple primary melanoma (MPM) patients. Genetic analy-
sis of CDKN2A (exons 1 alpha, 1 beta, 2 and 3), CDK4 (exon 2), MC1R (entire coding region) and
MITF (exon 9) was performed by direct sequencing in all patients. Five germline missense muta-
tions in the CDKN2A gene were identified in 6/52 (11%) FM patients from 5/34 (15%) families and
1/20 (5%) sporadic MPM patient: V59A, N71I, H83Q and P114L, mapping in exon 2 and T31M
mapping in exon 1 beta. In addition to disease-associated mutations, 3 polymorphisms in the
CDKN2A gene were detected: A148T in exon 2 in 7/52 (13%) FM patients and 1/20 (5%) sporadic
MPM patient, IVS3+29 3’UTR in 17/52 (33%) FM patients and 4/20 (20%) sporadic MPM patient
and IVS+69 in 3/52 (6%) FM patients and 5/20 (25%) sporadic MPM patients. MC1R variants were
identified in 30% of patients with the most frequently detected variants being V60L, R151C, Y152X,
R160W, and P268R. No germline mutations were identified in the specific hot spot of CDK4 or in
MITF exon 9. In conclusions, our results indicate that CDKN2A mutations account for a small pro-
portion of FM and sporadic MPM cases in our population, in line with other Italian studies, sug-
gesting a major role for low-penetrance genes and environmental factors.
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Changes in survivin subcellular localization correlates with different stages of differentiation
in normal and cancerous skin
K Dallaglio,1 T Petrachi,1 A Marconi,1 P Morandi,1 A Maiorana2 and C Pincelli1 1 Laboratory of
Cutaneous Biology, Institute of Dermatology, University of Modena and Reggio Emilia,
Modena, Italy and 2 Department of Laboratories and Pathologic Anathomy, University of
Modena and Reggio Emilia, Modena, Italy
The IAP (Inhibitor of Apoptosis Protein) protein survivin is detected in few adult cells, while it is
highly expressed in hyperproliferative conditions, including cancer. Nuclear survivin facilitates cell
cycle entry, whereas the cytoplasmic pool protects cells from apoptosis. Survivin is overexpressed
in cultured keratinocyte stem cells (KSC), and protects them from anoikis and UVB-induced apop-
tosis. As stem keratinocytes appear to be at the origin of squamous cell carcinoma (SCC), we eval-
uated survivin expression in normal and cancerous skin in vivo, by using a highly sensitive immuno-
hystochemistry (IHC) assay. We first demonstrated that survivin is not only localized in the cytoplasm
but also in the nucleus of normal adult keratinocytes, as also shown by western blotting. Nuclear
survivin is detected in basal and in few suprabasal keratinocytes. Nuclear survivin positive cells
were detected one every 10/11 basal keratinocytes. Suprabasal keratinocytes displaying nuclear sur-
vivin also express CK10. Nuclear, but not cytoplasmic survivin expression dramatically increases
in actinic keratosis and in SCC in situ, as compared to normal epidermis, and further increases in
SCC lesions. In addition, nuclear survivin is highest in poorly differentiated SCC and mostly local-
izes in deep, invasive lesions. Finally, in SCC cells, nuclear survivin positive cells seems to express
less CK10 as compared to normal skin. Alltogether, these data suggest that survivin subcellular local-
ization correlates with keratinocyte differentiation and is associated with undifferentiated and
more invasive SCC phenotype.
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TLR4 as a negative regulator of keratinocyte proliferation
G Iotzova-Weiss, SN Freiberger, I Kleiber-Schaaf, P Dziunycz, LE French and G Hofbauer
Dermatology Clinic Zurich, University Hospital Zurich, Zurich, Switzerland
Proliferation and differentiation are two sequential processes which drive the maturation of normal
keratinocytes till they reach their full differentiation status. However, abnormal proliferation of ker-
atinocyte is also a characteristic feature of tumor cells including squamous cell carcinoma (SCC)
cells. In this study, we want to delineate the inverse relationship between the proliferation of ker-
atinocytes and the pathogen-associated molecular pattern receptor TLR4. We observed that TLR4
surface expression in normal primary keratinocytes increases with subsequent passages in cell cul-
ture. In contrast, the expression of TLR4 in established highly proliferative squamous cell carci-
noma (SCC) cell lines was low, similar to the expression in normal keratinocytes at low passage
numbers. We found a stimulating effect of TLR4 blockade by a specific antibody on the prolifera-
tion rate of keratinocytes. In response to antibody-mediated blockade of TLR4, keratinocyte prolif-
eration increased greatly as assessed by the incorporation of BrDU. As an alternative blocking method,
we abrogated the interaction between TLR4 and its accessory protein MDII using a specific block-
ing peptide. Keratinocytes reacted with increased proliferation, though not to the same degree as
achieved by direct blocking of TLR4. Based on our results we hypothesize that TLR4 is a negative
regulator of keratinocyte proliferation and may be associated with the progression of SCC of the
skin. Such a regulatory function of TLR4 in keratinocyte proliferation has not been investigated yet.
This study delineates the regulatory role of TLR4 in keratinocyte proliferation and thus provide impor-
tant insight into the homeostasis of normal and tumor keratinocytes. Better understanding of a reg-
ulatory role for TLR4 is the basis for a later use in a therapeutic setting to stop keratinocyte prolif-
eration such as in squamous cell carcinoma of the skin and to induce keratinocyte proliferation such
as in wound healing.
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miRNA-205 in benign, premalignant and malignant skin
SH Omland, CM Lerche, E Biskup and R Gniadecki Dermatology, Faculty of Health Sciences,
University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark
MicroRNAs (miRNAs) are a group of short non-coding RNA molecules that control gene expression
posttranscriptional. They have emerged as regulators in oncogenesis. The role of MiR-205 in can-
cer is not well established. MiR-205 has recently been shown to be downregulated in malignant
melanoma and partly effecting it’s posttranscriptional role by targeting the 3’URT part of E2F, an
important regulator of cell cycle. Moreover miR-205 seemed to be involved in senescence of
melanoma cells. The expression of miR-205 in epithelial skin has recently been found to be broadly
expressed in nearly all stratified squamous epithelia. The same group found MiR-205 highly expressed
in aggressive oral squamous cell carcinoma (SCC)-lines with lower levels in minimally invasive SCC,
suggesting miR-205 acting as a tumor promoter in aggressive SCC. The purpose of our study was to
visualize the expression of miR205 in benign, premalignant and malignant skin by in situ hybridiza-
tion (ISH). The material constituted of formalin-fixed paraffin-embedded tissue samples from nor-
mal skin (6), keratoacanthomas (6), basal cell carcinomas (6), actinic keratoses (6), Bowen’s disease
(6) and squamous cell carcinomas (12): 6 well differentiated and 6 undifferentiated. We investigated
the level of miRNA-205 expression by ISH using a robust one-day protocol based on the use of
double digoxigenin-labeled LNA-DNA chimeric probe developed by Exiqon (Vedbæk, Denmark).
We used a concentration of has-miR-205 of 50nM. We found a broad expression of miRNA in all
stratified squamous epithelia. There was a tendency to upregulation of miR-205 in pre-malignant
and malignant epithelia compared to normal epithelia, evaluated as more intense blue staining after
ISH. The expression was rather homogenous and we were not able to identify specific cells with
higher expression of miRNA-205. Our findings correlate well with previous findings of up-regula-
tion of miRNA-205 in aggressive oral SCC. To further evaluate and quantify the levels of miRNA-
205 in malignant skin conditions real-time q-PCR will be performed.
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Increased expression of CD4 and IL-16 in cutaneous mast cells of mastocytosis patients
B Nedoszytko,1 M Lange,1 A Zawrocki,2 J Antoniewicz,3 M Zmijewski,3 M Zablotna,1
M Niedoszytko4 and W Biernat2 1 Dermatology, Medical University of Gdansk, Gdansk,
Poland, 2 Patomorphology, Medical University of Gdansk, Gdansk, Poland, 3 Histology,
Medical University of Gdansk, Gdansk, Poland and 4 Allergology, Medical University of
Gdansk, Gdansk, Poland
Mastocytosis is unusual heterogeneous disease associated with pathological accumulation of mast
cells (MC) in one or more organs. In majority of cases the disease is limited to the skin (cutaneous
mastocytosis–CM), however, in systemic mastocytosis (SM) other organs may be affected. Patho-
physiology of disease is not well established, but altered proliferation,differentiation and chemo-
taxis of MC may play an essential role in development of the disease. The aim of the study was to
assess the role of IL-16 in the pathogenesis of CM. Material and methods The study was conducted
on a group of 76 patients with mastocytosis and 42 healthy controls. From each subject skin biop-
sies and peripheral blood were collected for testing. The concentration of IL-16 in the serum was
measured using ELISA method. The presence of CD4, IL-16 and c-KIT immunoreactivity was eval-
uated in the skin biopsies by immunohistochemistry. The expression of IL-16, CD4, c-KIT, SCF and
CD9 genes were measured using qPCR method. Results We have shown, that the CD4, IL-16 and
c-KIT expression indices at protein level in MC increase in patients with CM. They were accompa-
nied by increased transcription level of CD4, CD9, IL-16, SCF and c-KIT genes. Likewise, IL-16
serum level in patients with mastocytosis was elevated in comparison to the healthy control group.
The mean level of IL-16 observed in patients group was 200,17±155,4 and was statistically higher
than observed in healthy controls (155,36±51,2, p=0,04). Conclusion The results of our analysis
suggest that increased expression of CD4 and interleukin 16 in the cutaneous MCs may play role
in chemotaxis of aberrant mast cells into the skin and development of clinical symptoms in masto-
cytosis.
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Association of mycosis fungoides with interleukin 2, 13 and TNF-alpha genes polymorphisms
B Nedoszytko, M Sokolowska-Wojdylo, M Zablotna, J Glen, H Lugowska-Umer and
J Roszkiewicz Dermatology Dept, Medical University of Gdansk, Gdansk, Poland
The genetic pathogenesis of cutaneous lymphomas has not been known very well. Only small num-
ber of data suggested association of T-cells cutaneous lymphomas with polymorphisms of oncogene
TP-53, interleukin 6, metalloproteinase 2 and angiotensin convertase genes have been published.
The association of the efficacy of phototherapy with polymorphism of endothelin- 1 gene was also
confirmed. The aim of our study was to establish the association of IL1A, 2, 8, 10, 13, TNF-alfa and
endotelin-1 genes polymorphism in Mycosis fungoides Material and methods 43 patients with clin-
ical diagnosis of Mycosis fungoides and 261 healthy persons were included in the study. 5 ml periph-
eral blood was collected from every one, genomic DNA was isolated and PCR-based methods for
polymorphisms analyses of selected genes were performed. Eight polymorphisms of 7 genes were
checked: −889 C/T of IL-1A, -166 G/T and -330 G/T of IL-2, −251A/T of IL-8, −1082 G/A of IL-10,
-1112 C/T of IL-13, -308 G/A of TNF-alfa and Lys198Arg of endotelin-1. The results were statisti-
cally analyzed with χ2 Pearson tests. Results Patients with Mycosis fungoides have revealed more
frequently the genotype -330 GG of IL-2, associated with high transcription rate, allele -308A of
TNF-alpha gene and genotype -1112 TT of IL-13 gene. There were no differences between com-
pared groups in the frequency of the both alleles and genotypes of the other analyzed genes. Con-
clusion Our results suggests that polymorphisms of IL-2, IL-13 and TNF-alpha genes may be involved
in the pathogenesis of Mycosis fungoides.
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Novel ptch1 mutations in patients with keratocystic odontogenic tumors as first hint to gor-
lin goltz syndrome detection
A Fabiano,1 G Ponti,1 L Pastorino,3 C Longo,2 G Bianchi Scarrà,4 S Seidenari1 and G Pellacani1 1
Department of Head and neck Surgery, Division of Dermatology, University of Modena and
Reggio Emilia, Modena, Italy, 2 Department of Laboratory, Pathological Anatomy and Forensic
Medicine, Division of Clinical Pathology, University Hospital of Modena and Reggio Emilia,
University of Modena and Reggio Emilia, Reggio emilia, Italy, 3 Department of Internal
Medicine and Medical Specialties (DiMI) University of Genoa, Genoa, Italy and 4 Laboratory
of Genetics of Rare Hereditary Cancers, IRCCS AOU San Martino-IST, Genoa, Italy
Keratocystic odontogenic tumors (kocts) are aggressive cystic tumors that arise sporadically or asso-
ciated with nevoid basal cell carcinoma syndrome (nbccs or gorlin syndrome). Nbccs is a rare
autosomal dominant disease mainly characterized by multiple basal cell carcinomas, kocts of the
jaws and a variety of other tumors. Ptch1 mutation can be found in sporadically or nbccs associ-
ated kocts. The goal of the current study was to assess whether a combined clinical and molecular
approach could be suitable for the detection of nbccs among patients with a diagnosis of kerato-
cystic odontogenic tumors (kocts). The authors collected keratocystic odontogenic tumors recorded
from 1991-2011. We found 18 out of 70 patients with kocts and/or multiple basal cell carcinoma
among them, thus meeting the clinical criteria for the diagnosis of nbccs. A wide inter- and intra-
familial phenotypic variability was evident in the families. Ameloblastomas were reported in two
nbccs probands carriers of the ptch1 germline mutations. Nine germline mutations in the ptch1
gene, 5 of them novel, were evident in 14 tested probands. The clinical evaluation of the kerato-
cystic odontogenic tumors can be used as screening for the detection of families at risk of nbccs.
Keratocystic odontogenic lesions are uncommon, and their discovery deserves the search for asso-
ciated cutaneous basal cell carcinomas and other benign and malignant tumors related to nbccs.
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All-Trans-Retinoic Acid and Cetuximab: Effects on Colon Adenocarcinoma Cell Viability
CC DeKlotz,1 E Cardin,2 J Maglione,3 T Ried2 and CA DeWitt1 1 Georgetown University Hospital
/ Washington Hospital Center, Washington, DC, 2 National Institutes of Health, National
Cancer Institute, Bethesda, MD and 3 Georgetown University School of Medicine,
Washington, DC
Epidermal growth factor receptor-Inhibitors (EGFR-I) treat many solid tumor malignancies; however,
they cause acneiform eruptions, affecting quality of life. Retinoids are a class of vitamin A derived
molecules that treat acneiform conditions and have a role in cancer treatment and prevention. The
purpose of this study is to explore the interaction between these two classes of medications on the
viability of neoplastic cells. Our primary outcome was non-inferiority of combined treatment of all-
trans-retinoic acid (ATRA) and cetuximab (an EGFR-I) when compared with cetuximab alone. Human
colon adenocarcinoma cell lines, DLD-1, SW480, Caco-2, and Colo320DM were treated with ATRA
(0, 5, 15, 30 μM) and cetuximab (0, 10, 100, 200 μg/mL) alone or in combination to comprise a
total of 16 experimental conditions. Viability assays were performed after 7 days of treatment and
the percentage of viability was calculated relative to control. Experiments were performed three
times with triplicates and results were expressed as the mean values of the viability. Significance of
the results was evaluated using Student t test. ATRA did not decrease the efficacy of cetuximab on
cell viability. In fact, viability was significantly decreased in all cell lines treated with the combi-
nation of ATRA and cetuximab as compared to treatment with cetuximab alone. According to these
studies, ATRA does not decrease the effectiveness of cetuximab in treating colon adenocarcinoma
cell lines. Interestingly, the combination of ATRA and cetuximab was superior in reducing the via-
bility of colon adenocarcinoma cell lines when compared with cetuximab alone. These studies
suggest that retinoids may be used to treat EGFR-I acneiform eruptions without impacting EGFR-I
tumor targeting efficacy. Further studies are needed to support our findings, which suggest additive
effects of ATRA and cetuximab in decreasing viability of colon adenocarcinoma cells.
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Two cases of erythrodermic CTCL expressing a TH1 immunophenotype
E Berti,1 B Vergani,1 D Fanoni,2 L Venegoni,1 G Saporiti,1 A Villa1 and F Onida2 1 Università degli
Studi di Milano-Bicocca, Milan, Italy and 2 Ospedale Maggiore Policlinico, Milan, Italy
Erythrodermic CTCL (E-CTCL) may present with a very aggressive-inflammatory course and can be
initially interpreted as a psoriasiform eruption. E-CTCL usually express a CD4+, TH2 immunophe-
notype of effector memory cells (mycosis fungoides) or of central memory cells T-cells (Sézary syn-
drome). However in some cases different cytotoxic immunophenotypes of αβ or γδ T-lymphocytes
may be expressed. Here our group report 2 cases of E-CTCL expressing the CD3+, CD4+, T-Bet+,
TIA-1-/GRB-, Ki-67+ immunophenotypic profile of TH1lymphocytes. In the first case, a 53 years old
man, cutaneous presentation simulating acute psoriasiform eruption was observed and treated by
cyclosporin. However after less than 12 months the patient became completely erythrodermic with
abundant desquamation and B-symptoms. In the second case, a man 75 years old, the lympho-
proliferative disorders was associated with a previous double transplant (1994 and 2000) for car-
diac failure and from a LNH B malignancy of the DLBCL type in 1997. From 2004 the patient showed
a psoriasiform desquamative eruption treated as psoriasis, but from the last year the cutaneous erup-
tion became completely erythrodermic. Histopathology in both cases was initially considered con-
sistent with psoriasis. T-bet is the master T-regulator of differentiation of TH1 and cytotoxic T-cells.
TH1 cells usually express T-bet nuclear positivity in absence of cytotoxic molecules TIA-1 and
Granzyme as in our cases. Confocal laser microscopic triple stainings was used to demonstrate the
double labelling of proliferating cells. While the first patient died after 2 years of aggressive course,
for progression and sepsis; the second patient is still living with disease. The existence of a subset
of CTCL expressing this rare phenotype may be considered in cases showing similar clinico patho-
logic features.
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Arsenic-induced skin cancers: pathomechanisms of aneuploidy
C Chang Dermatology, Kaohsiung Medical University, Kaohsiung, Taiwan
Arsenic has been classified as a group I human carcinogen by the International Agency for Research
on Cancer (IARC).Chromosomal abnormality (aneuploidy), oxidative stress and altered growth fac-
tors are proposed to involve in arsenic carcinogenesis. Arsenic-induced skin cancers include basal
cell carcinoma, squamous cell carcinoma and mostly Bowen’s disease. We performed the cytoge-
netic study on patients’lesional skin-derived cell line and aneuploidy was identified in the BD and
SCC, but not in BCC. We performed p53, gama-tubulin, Aurora A and Aurora B staining for confo-
cal microscopy and immunohistochemistry exams. Centrosome amplification is a common phe-
nomenon in lesional keratinocyte cytoplasm, which expressed p53 in nucleus. Aurora A or Aurora
B overexpression was identified in some but not all lesions. We exammed cultured keratinicytes and
skin equivalent after arsenic treatment. Centrosome amplification is a very early event induced in
both cultured keratinocytes and skin equivalent. Aurora A or Aurora B overexpression cannot be
induced in vitro. In arsenic-induced skin cancers, centrosome amplification plays an early and major
role in aneuploidy. Aurora A or Aurora B overexpression contributes in the longterm pathway of
carcinogenesis. p53 expression is a predisposing factor for centrosome abnormal duplication.
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Dermatofibrosarcoma protuberans: A clinicopathological, genetic (COL1A1-PDGFB), and
therapeutic study in Korean patients
M Roh, Z Zheng, S Lee and K Chung Department of Dermatology and Cutaneous Biology
Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
Background Dermatofibrosarcoma protuberans (DFSP) carries a translocation resulting in the
COL1A1-PDGFB fusion-gene which is responsible for platelet-derived growth factor beta receptor
(PDGFB) activation. Objective We sought to evaluate the clinicopathological, genetic and thera-
peutic features of DFSP in Korean patients. Methods The clinicopathological features were reviewed
in 36 patients. Multiplex reverse trenascriptase-polymerase chain reaction were carried out using
formalin-fixed, paraffin-embedded tissue, using specific primers for collagen type 1 alpha 1 (COL1A1)
and platelet-derived growth factor beta (PDGFB) in 17 patients. Results The median age at diagno-
sis was 37.4 years. The male: female ratio was 1: 1.12, and 44.4 % of tumors were located on the
trunk followed by the extremities and the head and neck. Twenty-five tumors (69.4%) were de novo
neoplasms and 11 (31.6%) recurred cases. All patients were treated with surgery: 33 (91.6%) cases
with MMS and 3 with WLE (8.4%). Median follow-up time was 33.7 months (range 6-79) and 1
patient had local recurrence. Among the 17 cases undergone multiplex RT-PCR, 15 cases showed
COL1A1-PDGFB fusion transcript. However, no clinical or histological parameter was found to be
associated with COL1A1-PDGCF fusion transcript. Conclusions Although DFSP is a slow-growing
tumor, multidisciplinary approach for management should be performed to minimize the risk for
local recurrence and limiting the functional and cosmetic morbidity.
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Exploring phenotypic heterogeneity in melanoma cultures
M Raaijmakers, D Widmer, T Herrera de Rolo, R Dummer and M Levesque Dermatology,
University hospital Zürich, Zürich, Switzerland
Cancer is heterogeneous. In a study of kidney cancer, genetic heterogeneity was found in tumor
lesions, where individual regions of the tumor and metastasis had different mutations, providing
support for the clonal evolution model of renal carcinoma. Evidence against such a model for
melanoma progression comes from contrary data whereby two distinct phenotypes can be observed
in vitro and in vivo: 1. the invasive phenotype is characterized by slow growing big cells that form
networks on Matrigel and have the potential to migrate through a membrane 2. the proliferative
phenotype is characterized by fast growing small cells that form separate clusters on Matrigel and
have less potential to migrate through a membrane. Melanoma cells can switch between these two
states and this switch may be triggered by environmental factors like hypoxia or chemotherapeutic
treatments, some of which appear to induce a more invasive phenotype in proliferative cells. This
induced switch is reversible as soon as the factor is released, which suggests that the phenotypes
arise from transcriptional or post-transcriptional control mechanisms and not from the acquisition
of new genetic mutations. We intend to determine the degree to which genetic factors may or may
not predispose melanoma cells to one of the two phenotypes. This hypothesis does not rule out the
possibility of transcriptional or post-transcriptional control mechanisms, which could still push the
predisposed phenotype to the other under the right conditions. We are collecting melanoma sam-
ples from patients admitted to our hospital. We make several cell cultures out of each sample, which
have given rise to both invasive and proliferative cultures derived from the same tumor. We are
preparing to deep sequence all cultures and check if we can identify mutations which favor one of
the two phenotypes. In addition, we will perform RNA -Seq analysis to identify candidate genes
and microRNAs for subsequent functional analysis. Finally, we will test these genes by knockdown
and overexpression experiments in vitro.
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